Research in contextEvidence before this studyPreoperative prediction of lymph node status is crucial for appropriate treatment planning in patients with colorectal cancer. However, current imaging modalities have limited sensitivity and specificity in predicting lymph node metastasis before surgery.Added value of this studyWe identified a novel serum 4-miRNA signature that could discriminate with high accuracy between serum miRNA profiles of colorectal patients with and without lymph node metastasis. Furthermore, an inclusive nomogram incorporating the 4-miRNA signature and computed tomography-reported lymph node status was constructed for prediction of lymph node metastasis in colorectal patients.Implications of all the available evidenceThis predictive nomogram model has great application potential in the non-invasive clinical evaluation of patients at risk of lymph node metastasis, and may be conveniently used to optimize treatment strategies by avoiding unnecessary lymph node -related procedures in colorectal cancer.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Colorectal cancer (CRC) is the third most frequent malignant tumor worldwide, representing the second leading cause of cancer-related mortality globally \[[@bb0005]\]. Lymph node (LN) metastasis is an important determining factor for the outcome of CRC \[[@bb0010]\]. Accurate preoperative prediction of LN status in CRC is of crucial importance for appropriate therapeutic decisions, such as the utilization of neoadjuvant and/or adjuvant chemotherapy for patients with LN metastasis, or the implementation of a more conservative approach to keep bowel resection to a minimum for patients without LN metastasis \[[@bb0015],[@bb0020]\]. To date, imaging modalities, including computed tomography (CT), are frequently used to predict LN involvement before surgery in clinical practice. These modalities, however, usually have limited sensitivity and specificity in predicting LN metastasis \[[@bb0025], [@bb0030], [@bb0035]\]. High-risk histopathologic features, including lymphatic or vascular invasion and poor differentiation, are also known to be predictors of LN metastasis \[[@bb0040]\]; however these data can only be obtained postoperatively. Therefore, there is an unmet need to develop novel non-invasive biomarkers to complement and improve current strategies for preoperative prediction of LN metastasis in patients with CRC.

Recent advancements in transcriptome profiling have highlighted the potential of small non-coding RNAs (ncRNAs) as tumor biomarkers \[[@bb0045]\]. MicroRNAs (miRNAs) are the most abundant and best characterized class of small ncRNAs, which regulate gene expression post-transcriptionally in multiple cancer-related processes including metastasis \[[@bb0050], [@bb0055], [@bb0060]\]. Accumulating evidence has provided insight into the role of dysregulated miRNAs as potential tumor markers to predict disease progression and metastasis \[[@bb0065],[@bb0070]\]. More importantly, circulating miRNAs originating from primary tumor tissues, are stably detectable in human body fluids \[[@bb0075], [@bb0080], [@bb0085]\]. These characteristics make circulating miRNAs ideal noninvasive indicators for tumor detection and prognosis \[[@bb0090]\]. Recently, differential expressions of circulating miRNAs have been reported to predict LN metastasis in various cancers \[[@bb0095], [@bb0100], [@bb0105]\]. In CRC, circulating miRNAs, such as miR-203 and miR-200c, have been reported to be independent predictors of LN metastasis \[[@bb0110],[@bb0115]\]. Although many studies have proposed circulating miRNAs to be predictors of metastasis, very few have attempted to identify circulating miRNA-based signatures for prediction of LN status before surgery \[[@bb0105],[@bb0120],[@bb0125]\]. Our group has recently identified a serum four-miRNA signature to preoperatively predict LN status in gastric cancer \[[@bb0120]\]. However, to date, there is no direct evidence as to whether a serum miRNA signature would enable superior prediction of LN status in other tumors, including CRC.

The combined analysis of multiple factors, rather than just a single biomarker---as could be provided by a nomogram---would be able to yield more powerful and accurate information in the clinical setting \[[@bb0130], [@bb0135], [@bb0140]\]. In the current study, we identified serum miRNAs that were significantly associated with LN metastasis by comprehensive miRNA profiling and RT-qPCR analysis, and then developed a serum miRNA-based panel in our CRC sample set. The serum miRNA-based panel was further combined with clinical risk factors to build a non-invasive nomogram for the preoperative prediction of LN status. Additionally, we assessed the predictive accuracy and clinical usefulness of the nomogram and validated it in an independent cohort.

2. Materials and methods {#s0025}
========================

2.1. Ethical statement {#s0030}
----------------------

All procedures performed in the study involving human participants were in accordance with the ethical standards of the Clinical Research Ethics Committee of Qilu Hospital, Shandong University and the Declaration of Helsinki. The experiments were undertaken with the understanding and written consent of each subject.

2.2. Study design {#s0035}
-----------------

Our study was conducted in three stage; a flowchart of the procedures is presented in [Fig. 1](#f0005){ref-type="fig"}. In the discovery stage, serum samples pooled from ten patients without LN metastasis (LN- group) and ten with LN metastasis (LN+ group) were subjected to high-throughput sequencing (HTS) to identify differentially expressed miRNAs. A miRNA was considered "significantly altered" only if the number of reads per million clean tags (RPM) value was larger than 1, along with a larger than two-fold change in its expression level in the LN- group vs. the LN+ group. Details for HTS and data analysis were described in the Supplementary Methods.Fig. 1Study flowchart.Fig. 1

In the training stage, candidate miRNAs were firstly examined by reverse transcription quantitative real-time PCR (RT-qPCR) in serum samples from 30 LN- and 30 LN+ patients. Subsequently, differentially expressed miRNAs were further tested in additional groups of 78 LN- and 80 LN+ patients. In combination, this amounted to 108 LN- and 110 LN+ patients (collected from October 2012 to December 2014), which were used as the training set to construct the panel for LN status prediction. Using the regression coefficients of the multivariate model to weight the power of each miRNA, a formula of miRNA-based panel was built to predict LN status, which was then used to calculate a risk score for each patient to reflect the risk of LN involvement. Receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC) were employed to assess the performance of miRNA-based panel for LN status prediction. Furthermore, independent validation was conducted using serum samples from another cohort of 98 LN- and 100 LN+ patients (the validation set, collected from January 2015 to December 2016) to validate the predictive accuracy of the constructed miRNA-based panel.

To build a quantitative nomogram, we used a multivariable logistic regression model to identify the preoperative clinical risk factors that were significantly correlated with LN status and then combined them with the miRNA-based panel to construct an inclusive model using the training cohort. Then, the performance of the inclusive nomogram was evaluated in the training cohort.

In the validation stage, the performance of the inclusive nomogram was appraised in the independent validation cohorts. The calibration of the nomogram was assessed with the calibration curve. The Hosmer-Lemeshow test was used to examine the goodness-of-fit of the nomogram model, and a ROC curve was employed to assess the discriminative ability of the nomogram. Moreover, decision curve analysis (DCA) was conducted to estimate the clinical utility of the nomogram in both cohorts \[[@bb0145]\].

2.3. Patients and sample preparation {#s0040}
------------------------------------

A total of 436 consecutive patients with CRC who were treated in the Department of General Surgery of the Qilu Hospital, Shandong University (Jinan, China) between October 2012 and December 2016 were enrolled in this study, according to the following inclusion criteria: (a) patients who underwent surgery with curative intent; (b) lymph node dissection was performed; (c) contrast-enhanced CT was performed \<10 days before surgery; (d) relevant clinical characteristics were available. The patients who had received preoperative therapy (radiotherapy, chemotherapy or chemoradiotherapy) or suffered from other tumor diseases at the same time were excluded.

Relevant clinical information including sex, age, preoperative histological differentiation and carcinoembryonic antigen (CEA) levels were collected from medical records. CEA was obtained from routine blood test before surgery, and the cutoff value was 5 ng/mL. CT scans were reviewed by two radiologists with \>10 years of experience, who were blinded to clinical characteristics and postoperative pathological findings. Patients with regional LN of \>1 cm and/or clusters of ≥3 lymph nodes were identified as clinically LN-positive, and patients without enlarged or clustered lymph nodes were regarded as clinically LN-negative \[[@bb0150]\]. Any disagreement was resolved by consultation.

Whole blood samples (5 mL) were collected from each participant by venipuncture. Serum was separated within 1 h of blood collection by centrifugation at 1500 ×*g* for 10 min at 4 °C to completely remove cell debris. The supernatant (serum) was then transferred to RNase/DNase-free tubes and stored at −80 °C until further processing.

2.4. RT-qPCR analysis of miRNA expression {#s0045}
-----------------------------------------

Briefly, 2 μg of total RNA was reversely transcribed into cDNA using the Mir-X miRNA First-Stand Synthesis Kit (Takara, Shiga, Japan). Then, 2 μL of cDNA was used for quantitative PCR analysis that was performed on the Bio-Rad CFX96 Detection System (Bio-Rad, Hercules, CA) using the SYBR Premix EX Taq (Takara, Shiga, Japan) and miRNA-specific primers (Ribobio, Guangzhou, China). All reactions were performed in triplicate to remove any outliers. In addition, miR-191-5p and U6 were selected as the reference genes according to our previous study \[[@bb0155]\]. The miRNA expression was normalized to the mean of these two reference genes. The relative expressions of miRNAs were determined using the 2^-dCt^ method.

2.5. Functional analysis of miRNAs {#s0050}
----------------------------------

HT-29 (NCI-DTP Cat\# HT-29, RRID:CVCL_0320) and SW480 (CLS Cat\# 300302/p716_SW-480, RRID:CVCL_0546) were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and cultured in a DMEM medium supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, USA). Transient transfection of chemically synthesized miRNA mimics (Ribobio, Guangzhou, China) was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer\'s instructions. Cell migration assays were performed as previously described \[[@bb0160]\]. The target genes of miRNAs were predicted using the online database mirDIP (<http://ophid.utoronto.ca/mirDIP/>), and the top 5% predicted targets were selected as input genes for the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis.

2.6. Statistical analysis {#s0055}
-------------------------

All the statistical analysis was performed with SPSS (version 18.0, Chicago, IL, USA), MedCalc 9.3.9.0 and R software (version 3.4.2; <http://www.Rproject.org>). *P*-values of 0.05 were considered to be statistically significant. The data distribution of each group was determined by the Kolmogorov-Smirnov test. Continuous variables were presented as the mean ± standard deviation (SD) or median (interquartile range) when the values were normally or non-normally distributed, respectively. Statistical differences between the groups were assessed using the Mann-Whitney *U* test and Student\'s *t*-test as appropriate. Categorical variables were presented as numbers (%) and analyzed using Pearson\'s chi-squared test or Fisher\'s exact test as appropriate. KEGG pathway enrichment analysis was conducted using the "clusterProfiler" package \[[@bb0165]\]. The performance of the nomogram was evaluated using calibration curve and ROC curve ("rms" package). DCA was performed using the "dca.R" ([decisioncurveanalysis.org](http://decisioncurveanalysis.org){#ir0015}).

3. Results {#s0060}
==========

3.1. Clinical characteristics {#s0065}
-----------------------------

[Table 1](#t0005){ref-type="table"} shows the baseline clinical and pathological characteristics, which were similar between the training and validation cohorts (all *P* \> .05). In addition, LN status was found to be significantly associated with preoperative CT-reported LN status and CEA levels in both cohorts.Table 1Characteristics of study participants in training set and validation set.Table 1Variable, N. (%)Discovery setTraining SetValidation Set*P\**LN (−)LN (+)TotalLN (−)LN (+)*P*TotalLN (−)LN (+)*P*SexMale10 (100)10 (100)126 (57.8)59 (54.6)67 (60.9)0.348116 (58.6)55 (56.1)61 (61.0)0.4860.871Female0 (0)0 (0)92 (42.2)49 (45.4)43 (39.1)82 (41.4)43 (43.9)39 (39.0)Age[a](#tf0005){ref-type="table-fn"}\<615 (50)3 (30)111 (50.9)61 (56.5)50 (45.5)0.103101 (51.0)54 (55.1)47 (47.0)0.2540.985≥615 (50)7 (70)107 (49.1)47 (43.5)60 (54.5)97 (49.0)44 (44.9)53 (53.0)Tumor locationColon5 (50)5 (50)74 (33.9)35 (32.4)39 (35.5)0.63569 (34.8)33 (33.7)36 (36.0)0.7310.846Rectum5 (50)5 (50)144 (66.1)73 (67.6)71 (64.5)129 (65.2)65 (66.3)64 (64.0)DifferentiationWell1 (10)0 (0)26 (12.1)16 (14.8)10 (09.3)0.07124 (12.3)14 (14.3)10 (10.3)0.0330.994Moderate8 (80)7 (70)140 (65.1)74 (68.5)66 (61.7)126 (64.6)69 (70.4)57 (58.8)Poor1 (10)3 (30)49 (22.8)18 (16.7)31 (29.0)45 (23.1)15 (15.3)30 (30.9)CT-reported LN statusLN-negative6 (60)3 (30)98 (45.0)62 (57.4)36 (32.7)0.0002101 (51.0)67 (68.4)34 (34.0)\<0.00010.217LN-positive4 (40)7 (70)120 (55.0)46 (42.6)74 (67.3)97 (49.0)31 (31.6)66 (66.0)CEA levelNormal7 (70)6 (60)142 (65.1)78 (72.2)64 (58.2)0.030131 (66.2)72 (73.5)59 (59.0)0.0310.826Abnormal3 (30)4 (40)76 (34.9)30 (27.8)46 (41.8)67 (33.8)26 (26.5)41 (41.0)Local invasionT1--T20 (0)0 (0)44 (20.2)42 (38.9)2 (1.8)\<0.000138 (19.2)37 (37.8)1 (1.0)\<0.00010.800T3--T410 (100)10 (100)174 (79.8)66 (61.1)108 (98.2)160 (80.8)61 (62.2)99 (99.0)Tumor size[b](#tf0010){ref-type="table-fn"}\<4.7 cm6 (60)2 (2)104 (47.7)57 (52.8)47 (42.7)0.08394 (47.5)52 (53.1)42 (42.0)0.0970.961≥4.7 cm4 (40)8 (8)92 (42.2)39 (36.1)53 (48.2)84 (42.4)36 (36.7)48 (48.0)Unkown0 (0)0 (0)22 (10.1)12 (11.1)10 (9.1)20 (10.1)10 (10.2)10 (10.0)[^1][^2][^3]

3.2. Selection of candidate miRNAs to predict LN metastasis {#s0070}
-----------------------------------------------------------

In the discovery stage, we identified 30 miRNAs that are differentially expressed between the serum samples from two groups of primary stage T3 CRC patients, including 10 LN- and 10 LN+ patients, using HTS (Table S1)·In the training stage, 22 miRNAs passed the quality test after miRNAs with Ct mean values higher than 35 and detection rates lower than 75% were excluded from the RT-qPCR analysis of 60 serum samples from 30 LN- and 30 LN+ CRC patients. Using RT-qPCR analysis, four differently expressed miRNAs (miR-122-5p, miR-146b-5p, miR-186-5p and miR-193a-5p), showing a consistent trend with the sequencing data (all *P* \< .05, Fig. S1). Then, we analyzed another 158 serum samples from CRC patients (80 LN- and 78 LN+) and confirmed the above phenomenon. The combined 108 LN - and 110 LN+ patients were used as the training set. As shown in [Fig. 2](#f0010){ref-type="fig"}, these four miRNAs showed significantly different expression between LN- and LN+ patients (all *P* \< .0001), with AUC values ranging from 0.681 to 0.811 (Table S2). We further evaluated the expression of these four miRNAs in the validation cohort consisting of 98 LN- and 100 LN+ patients. The alteration patterns of the miRNA expression in the validation set were consistent with those in the training set, with AUCs ranging from 0.722 to 0.796 (Fig. S2).Fig. 2The Box-whisker plots and ROC plots for miR-122-5p, miR-146b-5p, miR-186-5p and miR-193a-5p in the training set.(a--d) Relative expressions of miR-122-5p (a), miR-146b-5p (b), miR-186-5p (c) and miR-193a-5p (d) using RT-qPCR. (e-h) ROC analysis for the prediction of LN metastasis using miR-122-5p (e), miR-146b-5p (f), miR-186-5p (g) and miR-193a-5p (h).Fig. 2

The regulatory effects of these four miRNAs on tumor metastatic capacity of CRC cells were further confirmed, and the data showed that three miRNAs (miR-122-5p, miR-146b-5p and miR-186-5p) significantly promoted migration ability of HT-29 and SW480 cells, while miR-193a-5p induced the opposite effects (Fig. S3). Pathway analysis for these four miRNAs is shown in Fig. S4.

3.3. Development and validation of a 4-miRNA panel to predict LN status of CRC {#s0075}
------------------------------------------------------------------------------

Through logistic regression analysis, all four miRNAs were all identified as independent predictive factors for LN status in CRC ([Fig. 3](#f0015){ref-type="fig"}). A risk score formula of miRNA-based panel was built to predict LN status as follows: Logit (*P* = LN metastasis) = −1.916 + miR-122-5p\*0.495 + miR-146-5p\*0.869 + miR-186-59\*0.899 + miR-193a-5p\*(−0.377). Subsequently, we calculated the risk scores for all CRC patients, using this formula. Descriptive analyses for distributions of risk scores and LN status in both the training and validation sets showed that LN+ patients generally had higher risk scores ([Fig. 4](#f0020){ref-type="fig"}a and [4](#f0020){ref-type="fig"}d). The 4-miRNA panel yielded an AUC of 0.907 (95% CI: 0.860--0.942, [Fig. 4](#f0020){ref-type="fig"}b) in the training cohort and 0.870 (95% CI: 0.815--0.913, [Fig. 4](#f0020){ref-type="fig"}e) in the validation set (Table S2), while the AUC for CT-reported LN status was 0.623 (95%CI: 0.549--0.697) in the training set and 0.675 (95%CI: 0.600--0.750) in the validation set. The miRNA-based panel could provide better predictive efficacy than conventional CT-reported LN status (*P* \< .0001 in both training and validation sets). Moreover, the miRNA panel showed a good discriminatory ability in the CT-reported LN negative subgroup, with AUC values of 0.797 (95% CI: 0.701--0.892, [Fig. 4](#f0020){ref-type="fig"}c) in the training set and 0.764 (95%CI: 0.660--0.868, [Fig. 4](#f0020){ref-type="fig"}f) in the validation sets. When the patients were stratified based on the clinicopathological factors, a significant association between the miRNA-based panel and LN status was found in all subgroups (Fig. S5).Fig. 3Forest plot summary of analyses of LN status.Univariate and multivariate logistic regression for the four predictive miRNAs of LN metastasis in the training set. The squares on the transverse lines represent the odds ratio (OR), and the transverse lines represent the 95% confidence interval (95% CI).Fig. 3Fig. 4The distributions of the miRNA-based panel and its prediction values for LN status in training and validation sets.Distributions of the risk scores and LN status in the training (a) and validation (d) sets. LN status was marked with different colors. ROC analysis for the prediction of LN status using miRNA-based panel and CT-reported LN status in the training (b) and validation (e) sets. ROC analysis of miRNA-based panel in CT-reported LN negative subgroup in training (c) and validation (f) sets.Fig. 4

3.4. Development and validation of an individualized prediction nomogram {#s0080}
------------------------------------------------------------------------

Logistic regression analysis revealed the 4-miRNA panel and the CT-reported LN status were independent risk predictors of LN status ([Table 2](#t0010){ref-type="table"}). The model that incorporated the above independent predictors was developed and presented as the nomogram ([Fig. 5](#f0025){ref-type="fig"}a). The calibration plot of our nomogram showed the bias-corrected line lay close to the ideal curve (the 45-degree line), implying a good agreement between prediction and observation in the training set ([Fig. 5](#f0025){ref-type="fig"}b). The nonsignificant Hosmer-Lemeshow test statistic (*P* = .268) indicated a good fit to the model. The ROC analysis yielded an AUC of 0.913 (95%CI: 0.878--0.948, [Fig. 5](#f0025){ref-type="fig"}d) for the training set, which implied the discrimination performance was favorable.Table 2Univariate and multivariate logistic regression analysis of factors associated with lymph node metastasis in training set.Table 2Clinical variableSubgroupsUnivariate analysisMultivariate analysisOR95%CI*P*OR95%CI*P*SexFemale vs Male0.7700.451--1.3170.340Age≥61 vs \<611.5500.911--2.6380.106Tumor locationRectum vs Colon0.8860.507--1.5470.670DifferentiationWellRefModerate1.3890.590--3.2710.451Poor2.6670.998--7.1240.050CT-reported LN statusPositive vs Negative2.7551.591--4.7710.00032.6051.272--5.3350.009CEA levelAbnormal vs Normal1.8321.044--3.2140.0351.7270.817--3.6490.152miRNA-based panelHigh risk vs Low risk22.93711.124--47.295\<0.000122.90210.819--48.478\<0.0001[^4]Fig. 5The nomogram for preoperative prediction of LN status and its predictive performance.The nomogram to predict probability of LN metastasis for CRC patients in training set, with the miRNA-based panel and CT-reported LN status incorporated (a). Calibration curves of the nomogram in the training (b) and validation (c) sets (bootstrap 1000 repetitions). Nomogram-predicted probability of LN metastasis is plotted on the x-axis and actual probability is plotted on the y-axis. The dashed 45-degree line represents a perfect prediction by an ideal model, and the solid line represents the performance of our nomogram, of which a closer fit to the dashed line means a better prediction. ROC curves based on the nomogram for the probability of LN metastasis in the training (d, AUC = 0.913, 95%CI: 0.878--0.948) and validation (e, AUC = 0.883, 95%CI: 0.835--0.930) sets.Fig. 5

In agreement with the training set, the favorable calibration of the nomogram was confirmed in the validation set ([Fig. 5](#f0025){ref-type="fig"}c). The AUC of the validation set was 0.883 (95%CI: 0.835--0.930, [Fig. 5](#f0025){ref-type="fig"}e). Moreover, the DCA showed that if the threshold probability of a patient or a clinician is \>12%, using the nomogram to predict LN status adds more benefit than the "treat-all" or "treat-none" scheme. It also showed higher net benefit than CT-reported LN status ([Fig. 6](#f0030){ref-type="fig"}).Fig. 6Decision curve analysis for the nomogram and CT-reported LN status in the training (a) and validation (b) sets.The y-axis represents the net benefit, which was calculated by subtracting the proportion of false-positive patients from the proportion of true positive patients, weighting by the relative harm of giving up treatment compared to the negative effects by unnecessary treatment. The red dashed line represents the nomogram. The black dashed line represents CT-reported LN status. The gray solid line represents the hypothesis that all patients had LN metastasis. The black solid line represents the hypothesis that no patients had LN metastasis. The x-axis represents the threshold probability. The threshold probability is where the expected benefit of treatment is equal to the expected benefit of avoiding treatment. If the possibility of LN metastasis involvement of a patient is over the threshold probability, then a treatment strategy for LN metastasis should be adopted.Fig. 6

4. Discussion {#s0085}
=============

Non-invasive molecular markers to accurately predict LN status before surgery are urgently needed to optimize individually-tailored therapy in CRC. In the present study, we identified a novel serum 4-miRNA signature that discriminated with high accuracy between the serum miRNA profiles of CRC patients with and without LN metastasis. Furthermore, an inclusive nomogram incorporating the 4-miRNA signature and CT-reported LN status was constructed for the prediction of LN metastasis in CRC patients, which displayed satisfactory predictive accuracy in both the training and validation sets.

Circulating miRNAs are promising non-invasive cancer biomarkers with great translational potential to be used in personalized medicine. Nonetheless, despite some advances having been made, much research has focused on a few preselected miRNAs, leaving the majority of miRNAs unexplored. In this study, differential miRNAs expression profiles were initially determined in pooled serum samples from CRC patients with and without LN metastasis using high-throughput sequencing during the discovery stage. With this foundation, significantly differentially expressed miRNAs were further identified by RT-qPCR validation. To the best of our knowledge, this is the first comprehensive analysis of predictive biomarkers for LN metastasis based on circulating miRNA expression profiles in CRC patients.

MiRNAs are known to be secreted by various cell types and can be shuttled between cells, and thus modulate gene expressions and cellular activities. Dysregulation of miRNA expression in different types of cells in tumor microenvironments has been documented to contribute to tumor metastasis \[[@bb0170], [@bb0175], [@bb0180]\]. Considering circulating miRNAs may arise from heterogeneous sources, we not only validated the expression of candidate miRNAs in CRC serum, but also confirmed their effect on the metastatic capacity of CRC cells. Thereafter, the four most promising miRNAs were selected, on the basis that they exhibited differential expression associated with LN metastasis and could exert regulatory effects on the metastatic behavior of CRC cells. Functional enrichment analysis of the KEGG signaling pathway showed the top 20 pathways involved, such as the PI3K-Akt signaling pathway, suggesting these miRNAs serve a critical role in CRC metastasis. Furthermore, these miRNAs have been previously reported to be involved in metastasis of CRC \[[@bb0185], [@bb0190], [@bb0195], [@bb0200], [@bb0205], [@bb0210], [@bb0215]\]. These findings, together with our observations, suggest the potential use of the four circulating miRNAs as predictive biomarkers for LN metastasis in CRC patients. However, we failed to detect consistent changes in serum miR-203 and miR-200c as previously reported in CRC patients \[[@bb0110],[@bb0115]\]. This conflict in the result may be due to varying ethnic compositions in the samples.

Nomograms are the visualization of statistical models specifically developed to optimize the predictive accuracy of individuals. Preoperative nomograms estimating LN metastases can aid clinicians in identifying patients who may derive greater clinical benefit from more extensive surgery \[[@bb0220], [@bb0225], [@bb0230], [@bb0235]\]. In the current study, we postulated that an inclusive model incorporating a serum miRNA signature and clinical risk factors might improve the accuracy of node staging. Thus, we built a risk score formula of the four-miRNA panel that could provide better predictive efficacy as compared to conventional CT scans, and then we combined all significant independent predictors, including the miRNA-based panel and CT-reported LN status, to a nomogram. Wu et al. previously also presented a noninvasive nomogram model, with an AUC of 0.788 for prediction of LN status in CRC \[[@bb0150]\]. Their model incorporates a radiomics signature and clinical risk factors, but lacks sensitive and specific molecular markers. The miRNA-based prediction models for operatively predicting LN status have recently been successfully developed in breast and hepatocellular cancer \[[@bb0140],[@bb0240]\]. Our study is the first to investigate the usefulness of a 4-miRNA panel as an effective molecular approach for the preoperative prediction of LN status in CRC. Our data suggest this miRNA-based panel could provide clinicians with relatively accurate LN status assessment, and the nomogram may be a useful tool for preoperative prediction of LN metastasis, aiding in individualized management decisions, and ultimately contributing to improved survival among CRC patients.

The most important argument for the adoption of the nomogram into clinical use is to justify whether nomogram-assisted decisions in management could improve patient outcomes. However, current measures of prediction performance, such as predicted-versus-observed tests for model calibration, AUC or concordance index (often used interchangeably) cannot fulfil this prospect. Therefore, we used decision analysis curves to estimate the clinical utility of our prediction nomogram based on threshold probability---the probability at which the clinician or patient would proceed with some action \[[@bb0145],[@bb0235],[@bb0245],[@bb0250]\]. The decision curves showed that if the threshold probability is higher than 12%, using the nomogram to predict LN status adds more net benefit than the "treat-all" or "treat-none" scheme.

Our study has the following strengths: A relatively large number of enrolled participants, genome-wide miRNA profiling followed by training set and validation set, identification of a novel miRNA-based panel, and construction of a clinically useful nomogram, which indicates the clinical practicality and innovation of our research. Despite the relatively high predictive ability of our miRNA-based panel, one limitation should be taken into consideration: The present study is a single-center retrospective analysis, with limited generalizability as all subjects are of the same ethnicity, and the distribution of clinical features might be distinct in other regions, making it unsuitable for other races and areas. Therefore, our results should be further validated by prospective research in a multicenter trial on diverse ethnic populations.

In conclusion, our results suggest that the serum miRNA-based panel obtained by gene expressing profiling can be combined with CT evaluation to improve the accuracy of preoperative prediction of LN status. This predictive nomogram model has great applicability potential in the non-invasive clinical evaluation of patients at risk of LN metastasis, and may be conveniently used to optimize treatment strategies by avoiding unnecessary LN-related procedures in CRC.
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Supplementary Tables and FiguresImage 1Detail clinical information of enrolled patientsImage 2

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ebiom.2018.09.052>.

[^1]: *P*\*: the difference between the training set and validation set.

[^2]: The average age was 61.

[^3]: Tumor size measured in greatest transverse diameter (cm), and the mean was 4.7 cm.

[^4]: OR: odds ratio; CI: confidence interval.
